Spinraza Recent News
Morgan Stanley Takes A Breather On Biogen, Downgrades Stock
Couldn't Make It To Leerink's Global Healthcare Conference? Here Are The Highlights From Day One
Don't Get Too Excited About Biogen's Q4 Earnings
Why Spinraza Is The Only Exciting Thing About Ionis Pharmaceuticals
Spinraza Cost Estimates Could Reignite The Drug Pricing Debate
Ionis Pharma's Target Lifted To $68 Following More Favorable Spinraza Ramp Estimates
Why The Biogen-Ionis News Is A Boon For AveXis